Merck & Co.'s third quarter 2009 earnings call provided several indicators of its short-term stock movement. The company showcased robust product performance, especially in key brands like SINGULAIR and JANUVIA. The major factor influencing investor sentiment is the imminent merger with Schering-Plough, which promises synergies and enhanced market capabilities. However, challenges like the revenue decline in the cholesterol segment and competitive pressures in certain markets could temper enthusiasm. Overall, the market is likely to react positively to the strong financial performance and merger prospects in the short term.

[1]